Anyplex™ II HPV HR Detection meets the international guidelines for primary cervical cancer screening
Jan 20, 2016
- Clinical study conducted by the research team of Dr. Chris Meijer, a leading scientist in the field of HPV.
- The product is now geared up for the primary cervical cancer screening market, accelerating the company’s movements in global HPV market.
Anyplex™ II HPV HR Detection designed for simultaneous detection and genotyping of 14 high-risk (HR) HPV has been proved to be effective for the primary cervical cancer screening by conducting 876 samples for the validation. With the result, Seegene Inc. (096530.KQ) will focus on penetrating into the primary cervical cancer screening market.
On January 20th, 2016, Seegene announced that Anyplex™ II HPV HR Detection meets the international consensus validation metrics for HPV DNA tests for cervical cancer screening and makes itself recognized as the first multiple detection Real-time PCR in the world. Dr. Chris Meijer, the world foremost researcher on HPV study, who established the international guidelines for the primary cervical cancer screening, said that Anyplex™ II HPV HR Detection showed its performance as the primary cervical cancer screening and HPV genotyping simultaneously. An official article has been listed on Journal of Clinical Virology.
Dr. Eugene Kim, executive director of Seegene said, “HPV test in regular checkups is the most efficient method to find a risk of developing cervical cancer. Anyplex™ II HPV HR Detection is considered one of the most efficient technologies for proper treatments and prevention of cervical cancer by providing information of HPV infection with its exact genotype. Dr. Kim also stated that “Presentations on the product at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Copenhagen in Denmark in April 2015, was received enthusiastically.”
Over 99 percent of all cases of cervical cancer are caused by HPV infections. However, it requires relatively long period of time to develop to cervical cancer from HPV infection. Therefore, regular screening test for women is highly recommended for the early detection to prevent from cervical cancer as it is simple and cost effective to treat infection in the early stages.
